Will GLP-1 weight-loss drugs slow down DME growth?

Will GLP-1 weight-loss drugs slow down DME growth? The data suggests the exact opposite. There’s been massive debate in the industry about how GLP-1 adoption might impact categories like CPAP machines and sleep therapy. But recent patient data shows an unexpected trend: Increased healthcare engagement is actually driving HIGHER sleep study participation and equipment diagnosis. Key takeaways for HME/DME operators: 📊 Awareness drives diagnosis: Patients taking proactive steps for their health are more likely to complete sleep evaluations and stick to therapy. 📈 Resilient Valuations: Strategic buyers and private equity groups continue actively acquiring strong, diversified regional DME providers. 💡 Product Diversification: Winning providers are expanding their portfolio across respiratory, mobility, and remote monitoring to build resilient revenue streams. Technology and patient behavior are evolving, but the core need for trusted, home-based medical equipment remains stronger than ever. #DMETrends #SleepApnea #HealthcareBusiness #HME #HealthcareMergers